<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049980</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/21/0328</org_study_id>
    <nct_id>NCT05049980</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction With the Management of a Stopped Pregnancy in the First Trimester</brief_title>
  <acronym>MYFEFACY</acronym>
  <official_title>Evaluation of the Efficacy, Tolerance of the Treatment, and Patient Satisfaction During the Management of an Arrested Pregnancy in the First Trimester According to the New Toulouse University Hospital Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical practice recommendations highlight the fact that the patient's choice concerning&#xD;
      the management of her aborted pregnancy in the first trimester should be privileged, after&#xD;
      clear and appropriate information on the available treatments, in order to improve his&#xD;
      experience and reduce the negative psychological symptoms that can generate an alteration in&#xD;
      the quality of life, in the aftermath of the loss of pregnancy.&#xD;
&#xD;
      The present study will describe the efficacy, satisfaction and tolerance of patients&#xD;
      benefiting from medical treatment with Mifégyne® and MisoOne® versus those benefiting from&#xD;
      surgical treatment by endo-uterine aspiration for the management of a pregnancy stopped&#xD;
      during the first trimester at the Toulouse University Hospital&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Inclusion day (day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Inclusion day (day 0)</time_frame>
    <description>Completing the satisfaction questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pregnancy Loss, Early</condition>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients choosing medical treatment with Mifégyne® and MisoOne®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients choosing surgical treatment by endo-uterine aspiration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical treatment with Mifégyne® and MisoOne®</intervention_name>
    <description>When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.</description>
    <arm_group_label>Medical treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endo-uterine aspiration</intervention_name>
    <description>When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.</description>
    <arm_group_label>Surgical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any adult patient presenting to the gynecological emergency department of the Paule de&#xD;
             Viguier Hospital in Toulouse for whom a diagnosis of an arrested pregnancy in the&#xD;
             first trimester is made&#xD;
&#xD;
          -  Whose cranio-caudal length of the embryo measured by ultrasound is less than 25 mm or&#xD;
             having a clear egg&#xD;
&#xD;
          -  Having agreed to the study (written or verbal) after clear and fair information&#xD;
&#xD;
          -  Who understands and reads French&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical contraindication to treatment with Mifégyne® or MisoOne®&#xD;
&#xD;
          -  Hemodynamically unstable patient requiring urgent surgical treatment.&#xD;
&#xD;
          -  Protected adult patient (guardianship, curatorship, safeguard of justice)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mickael ALLOUCHE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mickael ALLOUCHE, MD</last_name>
    <phone>567771118</phone>
    <phone_ext>+33</phone_ext>
    <email>allouche.m@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiriata ROOPINIA</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mickael ALLOUCHE</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mickael ALLOUCHE</last_name>
      <phone>567771118</phone>
      <phone_ext>+33</phone_ext>
      <email>allouche.m@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

